Treatments and Outcomes Among Patients with Sydenham Chorea: A Meta-Analysis

Abstract

**IMPORTANCE** Sydenham chorea is the most common acquired chorea of childhood worldwide; however, treatment is limited by a lack of high-quality evidence.

**OBJECTIVES** To evaluate historical changes in the clinical characteristics of Sydenham chorea and identify clinical and treatment factors at disease onset associated with chorea duration, relapsing disease course, and functional outcome.

**DATA SOURCES** The systematic search for this meta-analysis was conducted in PubMed, Embase, CINAHL, Cochrane Library, and LILACS databases and registers of clinical trials from inception to November 1, 2022 (search terms: [Sydenham OR Sydenham’s OR rheumatic OR minor] AND chorea).

**STUDY SELECTION** Published articles that included patients with a final diagnosis of Sydenham chorea (in selected languages).

**DATA EXTRACTION AND SYNTHESIS** This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Individual patient data on clinical characteristics, treatments, chorea duration, relapse, and final outcome were extracted. Data from patients in the modern era (1945 through 2022) were entered into multivariable models and stratified by corticosteroid duration for survival analysis of chorea duration.

**MAIN OUTCOMES AND MEASURES** The planned study outcomes were chorea duration at onset, monophasic course (absence of relapse after ≥24 months), and functional outcome (poor: modified Rankin Scale score 2-6 or persisting chorea, psychiatric, or behavioral symptoms at final follow-up after ≥6 months; good: modified Rankin Scale score 0-1 and no chorea, psychiatric, or behavioral symptoms at final follow-up).

**RESULTS** In total, 1479 patients were included (from 307 articles), 1325 since 1945 (median [IQR] age at onset, 10 [8-13] years; 875 of 1272 female [68.8%]). Immunotherapy was associated with shorter chorea duration (hazard ratio for chorea resolution, 1.51 [95% CI, 1.05-2.19]; \( P = .03 \)). The median chorea duration in patients receiving 1 or more months of corticosteroids was 1.2 months (95% CI, 1.2-2.0) vs 2.8 months (95% CI, 2.0-3.0) for patients receiving none (\( P = .004 \)). Treatment factors associated with monophasic disease course were antibiotics (odds ratio [OR] for relapse, 0.28 [95% CI, 0.09-0.85]; \( P = .02 \)), corticosteroids (OR, 0.32 [95% CI, 0.15-0.67]; \( P = .003 \)), and sodium valproate (OR, 0.33 [95% CI, 0.15-0.71]; \( P = .004 \)). Patients receiving at least 1 month of corticosteroids had significantly lower odds of relapsing course (OR, 0.10 [95% CI, 0.04-0.25]; \( P < .001 \)). No treatment factor was associated with good functional outcome.

(continued)
CONCLUSIONS AND RELEVANCE  In this meta-analysis of treatments and outcomes in patients with Sydenham chorea, immunotherapy, in particular corticosteroid treatment, was associated with faster resolution of chorea. Antibiotics, corticosteroids and sodium valproate were associated with a monophasic disease course. This synthesis of retrospective data should support the development of evidence-based treatment guidelines for patients with Sydenham chorea.

Introduction

Sydenham chorea (SC) is an autoimmune neuropsychiatric disorder associated with prior group A streptococcal (GAS) infection.1 It is 1 of the major manifestations of acute rheumatic fever (ARF) and remains the most common acquired chorea of childhood worldwide, including some high-income settings.2,3 In SC, chorea of the extremities, and, often, chorea of the face, tongue, and trunk are usually accompanied by hypotonia and emotional or behavioral disturbances, most frequently emotional lability.1 In a subgroup with severe disease, there is complete loss of tone and voluntary movements (chorea paralytica).4,5 Most patients recover fully within 6 to 9 months, but symptoms persist in up to 40% of patients,1,6-8 and relapses occur in 16%-42%.9-12 Except for antibiotics, there is limited consensus regarding treatment.1,13 Only 3 small randomized clinical trials (RCTs) assessing immunotherapy for SC have been reported,14-16 and treatment strategies vary widely, with corticosteroid use in recent cohorts ranging from 16% to 75%, and steroid regimens differing even within centers.17-20 Herein we present a comprehensive evidence synthesis of published SC cases with individual patient data (IPD), with the aims of describing the clinical features and management of SC and of identifying associations between early clinical and treatment factors and disease course and outcome.

Methods

Literature Search and Data Collection

For this meta-analysis, PubMed, Embase, CINAHL, Cochrane Library, and LILACS (Literatura Latino-Americana e do Caribe em Ciências da Saúde) databases and registers of clinical trials were searched from inception to November 1, 2022 (search terms: [Sydenham OR Sydenham's OR rheumatic OR minor] AND chorea). eFigure 1 and eTable 1 in Supplement 1 provide search and article selection details. Cases from articles in selected languages (English, French, Spanish, Portuguese, and Italian) with IPD were included if they included acute or subacute chorea onset and a final diagnosis of SC according to the authors. If not provided, IPD was requested from the authors of articles published since January 1, 2012, reporting at least 10 cases. Individual patient data on demographics, preexisting conditions, symptoms, severity at the first SC episode, ARF manifestations, treatments, and outcomes were collected using a standardized proforma (eMethods 1 in Supplement 1). This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.

Study Outcomes

We evaluated 3 main outcomes: chorea duration at the first SC episode, relapsing disease course, and final functional outcome. Relapsing disease course was defined as the occurrence of at least 1 relapse (at any time); monophasic disease course was defined as no relapse after a minimum of 24 months’ follow-up. Poor functional outcome was defined as a modified Rankin Scale (mRS) score of 2 to 6 or persisting chorea or psychiatric or behavioral symptoms at final follow-up 6 or more months after
the last SC episode. Good functional outcome was defined as an mRS score of 0 to 1 and no chorea or psychiatric or behavioral symptoms at final follow-up (at any time).

**Statistical Analysis**

For historical comparison, patients with disease onset (or if unknown, publication year) before 1945 (when penicillin first became commercially available and 1 year after the first ARF diagnostic criteria were established) were compared with patients from the modern era (1945 through 2022) using the χ² or Fisher exact test for nominal data, Mann-Whitney U test for continuous or ordinal data, and Kaplan-Meier survival analysis with the log-rank test for chorea duration. To optimize data reliability and relevance, only data since 1945 were included in subsequent analyses. Denominators for descriptive data varied according to data availability. Symptomatic medications were grouped into pharmacological classes, and differences in clinician-reported benefit were tested using pairwise χ² tests with Bonferroni-corrected P values. Medication classes given to fewer than 10 patients were not included. To assess the 3 main outcomes, 3 separate multivariable models were applied: a Cox proportional hazards regression model for chorea duration at first episode (including symptomatic medications and immunotherapy as time-varying features) and logistic regression models for relapsing disease course and functional outcome. Missing values for 27 variables (eTable 2 in Supplement 1) underwent hot-deck imputation prior to multivariable modeling (eMethods 2 in Supplement 1). Sensitivity analyses were conducted for year of onset and missingness (eMethods 3 in Supplement 1). In further univariate analyses of the nonimputed data, patients were grouped according to corticosteroid treatment duration at the first episode (none, <1 month, or ≥1 month) to evaluate associations with chorea duration (Kaplan-Meier survival analysis) and relapsing course (Fisher exact tests). Two-tailed P < .05 was regarded as significant. Analyses used Python, version 3.10 (Python Software Foundation) with statsmodels, lifelines, and hail packages.

**Results**

**Historical Trends**

We identified 1479 patients with IPD (median [IQR] age at onset, 10 [8-13] years in 1354 patients; 985 of 1426 [69.1%] female and 441 of 1426 [30.9%] male) were identified from 307 articles. Compared with 1325 patients identified in the modern era (1945 to 2022), 154 patients with onset before 1945 had more frequent fever (11 of 20 [55.0%] vs 66 of 458 [14.4%]) and worse severity (median [IQR] mRS, 4 [3-4] vs 3 [3-4]) during the first SC episode, longer hospitalization (median, 40 [25-62] days vs 21 [10-35] days), more frequent arthritis or arthralgia (48 of 145 patients [33.1%] vs 275 of 1118 patients [24.6%]), shorter chorea duration at first episode (median IQR, 2.0 [1.0-3.0] months vs 3.0 [1.2-6.0] months) and worse long-term outcome (5 of 13 patients [39%] vs 47 of 338 patients [13.9%] with poor functional outcome) (Figure 1 and eTable 3 in Supplement 1).

**Demographics and Background History**

In total, 1325 patients from 50 countries had disease onset since 1945 (Table 3; eTables 4-7 in Supplement 1; Figure 2A and B). Median (IQR) age was 10 (8-13) years in 1202 patients, and 1265 of 1317 patients (96.1%) were younger than 18 years (Figure 2C). Of 1272 patients, 875 (68.8%) were female and 397 (31.2%) were male. Of 1305 patients, 1111 (85.1%) were from populations considered at low risk for ARF; 33 of 435 (7.6%) had a family history of ARF. Of 442 patients, 27 (6.1%) had a history of other autoimmune or inflammatory diseases and 37 of 418 (8.9%) had preexisting psychiatric, neurologic, or neurodevelopmental disorders.

**Clinical Features of the First Episode of Sydenham Chorea**

Preceding symptoms of infection were reported in 259 of 485 patients (53.4%). Initial presenting SC symptoms were motor in 325 of 405 patients (80.2%), psychiatric or behavioral in 27 of 405 patients...
(6.7%) and both combined in 53 of 405 patients (13.1%). Chorea involved the limbs in 572 of 574 patients (99.7%), face in 234 of 309 patients (75.7%), and trunk in 136 of 287 patients (47.4%); 208 of 664 patients (31.3%) had hemichorea. Of 334 patients, 227 (70.1%) had impaired mobility, 177 of 264 patients (67.0%) had impaired object manipulation, 210 of 337 patients (62.3%) had impaired speech, and 57 of 251 patients (22.7%) had impaired chewing or swallowing. Of 484 patients, 312 (64.5%) had psychiatric or behavioral symptoms, most frequently emotional lability, anxiety, irritability, hyperactivity, and aggressive behavior (eFigure 2 in Supplement 1). Mental health...
Table. Clinical Characteristics, Treatments, and Outcomes in 1325 Patients with SC Since 1945

<table>
<thead>
<tr>
<th>Characteristic, Treatment, or Outcome</th>
<th>Patients, No./total No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics and background history</strong></td>
<td></td>
</tr>
<tr>
<td>Age at onset, y (n = 1202)</td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>10.9 (5.0)</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>10.3 (8.0-13.0)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>875/1272 (68.8)</td>
</tr>
<tr>
<td>Male</td>
<td>397/1272 (31.2)</td>
</tr>
<tr>
<td>Family history of ARF</td>
<td>33/435 (7.6)</td>
</tr>
<tr>
<td>Preexisting psychiatric, neurologic, or neurodevelopmental disorders</td>
<td>37/418 (8.9)</td>
</tr>
<tr>
<td>Current economic classification of country of residence or health care provisionb</td>
<td></td>
</tr>
<tr>
<td>Income</td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>598/1317 (45.4)</td>
</tr>
<tr>
<td>Upper-middle</td>
<td>638/1317 (48.4)</td>
</tr>
<tr>
<td>Lower-middle</td>
<td>79/1317 (6.0)</td>
</tr>
<tr>
<td>Low</td>
<td>2/1317 (0.2)</td>
</tr>
<tr>
<td>Low population ARF risk</td>
<td>1111/1305 (85.1)</td>
</tr>
<tr>
<td><strong>Clinical features of the first SC episode (within first 3 mo after initial presentation)</strong></td>
<td></td>
</tr>
<tr>
<td>Symptoms of infection preceding SC onset</td>
<td>259/485 (53.4)</td>
</tr>
<tr>
<td>Time between infection and SC onset, wk (n = 158/259)</td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>9.9 (12.1)</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>8.0 (3.0-14.0)</td>
</tr>
<tr>
<td>Antibiotics given before onset of ARF/SC</td>
<td>43/347 (12.4)</td>
</tr>
<tr>
<td>Hemichorea</td>
<td>208/664 (31.3)</td>
</tr>
<tr>
<td>Limb</td>
<td>572/574 (99.7)</td>
</tr>
<tr>
<td>Face</td>
<td>234/309 (75.7)</td>
</tr>
<tr>
<td>Trunk involvement</td>
<td>136/287 (47.4)</td>
</tr>
<tr>
<td>Impaired mobility</td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>227/324 (70.1)</td>
</tr>
<tr>
<td>Severe: bedridden</td>
<td>38/324 (11.7)</td>
</tr>
<tr>
<td>Impaired speech</td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>210/337 (62.3)</td>
</tr>
<tr>
<td>Severe: unable to speak</td>
<td>11/337 (3.3)</td>
</tr>
<tr>
<td>Impaired object manipulation</td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>177/264 (67.0)</td>
</tr>
<tr>
<td>Severe: fully dependent for self-care and feeding</td>
<td>62/264 (23.5)</td>
</tr>
<tr>
<td>Impaired chewing or swallowing</td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>57/251 (22.7)</td>
</tr>
<tr>
<td>Severe: nasogastric tube or parenteral feeding</td>
<td>16/251 (6.4)</td>
</tr>
<tr>
<td>Hypotonia</td>
<td>151/246 (61.4)</td>
</tr>
<tr>
<td>Motor impersistence (milkmaid’s grip)</td>
<td>66/125 (52.8)</td>
</tr>
<tr>
<td>Abnormal tongue movements (darting tongue)</td>
<td>53/146 (36.3)</td>
</tr>
<tr>
<td>Muscle weakness</td>
<td>63/196 (32.1)</td>
</tr>
<tr>
<td>Any psychiatric or behavioral symptom</td>
<td>312/484 (64.5)</td>
</tr>
<tr>
<td>Emotional liability</td>
<td>139/415 (33.5)</td>
</tr>
<tr>
<td>Fever</td>
<td>66/458 (14.4)</td>
</tr>
<tr>
<td>Worst mRS score (n = 460)</td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>3.2 (0.9)</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>3.0 (3.0-4.0)</td>
</tr>
<tr>
<td>Carditis or valvulitis</td>
<td>610/1151 (53.0)</td>
</tr>
<tr>
<td>Arthritis or arthralgia</td>
<td>275/1118 (24.6)</td>
</tr>
<tr>
<td>Erythema marginaturn or subcutaneous nodules</td>
<td>31/836 (3.7)</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Characteristic, Treatment, or Outcome</th>
<th>Patients, No./total No. (%)*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Investigation findings at the first SC episode (within first 3 mo after initial presentation)</strong></td>
<td></td>
</tr>
<tr>
<td>ASOT elevated</td>
<td>393/547 (71.8)</td>
</tr>
<tr>
<td>Anti-DNase B elevated</td>
<td>80/134 (59.7)</td>
</tr>
<tr>
<td>Throat culture positive for GAS</td>
<td>68/182 (37.4)</td>
</tr>
<tr>
<td>Elevated ESR</td>
<td>255/470 (54.3)</td>
</tr>
<tr>
<td>Elevated CRP</td>
<td>94/340 (27.6)</td>
</tr>
<tr>
<td><strong>ECG findings</strong></td>
<td></td>
</tr>
<tr>
<td>Prolonged PR interval</td>
<td>41/337 (12.2)</td>
</tr>
<tr>
<td>Any other abnormality</td>
<td>16/177 (9.0)</td>
</tr>
<tr>
<td><strong>Abnormal brain structural MRI</strong></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>43/225 (19.1)</td>
</tr>
<tr>
<td>Basal ganglia abnormal (focal swelling or T2/FLAIR hyperintensity)</td>
<td>16/223 (7.2)</td>
</tr>
<tr>
<td>White matter abnormal (focal T2/FLAIR hyperintensity)</td>
<td>15/224 (6.7)</td>
</tr>
<tr>
<td><strong>Abnormal EEG findings (slow/disorganized activity and/or epileptic activity)</strong></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>84/153 (54.9)</td>
</tr>
<tr>
<td>Focal or diffuse slow or disorganized activity</td>
<td>77/149 (51.7)</td>
</tr>
<tr>
<td>Epileptic activity (epileptic discharges or electrographic seizures)</td>
<td>7/147 (4.8)</td>
</tr>
<tr>
<td><strong>Abnormal CSF findings</strong></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>8/32 (25.0)</td>
</tr>
<tr>
<td>Pleocytosis ≥5 cells/μL (nonbloody tap only)</td>
<td>4/31 (12.9)</td>
</tr>
<tr>
<td>Intrathecal oligoclonal bands (present in CSF unmatched in serum)</td>
<td>2/26 (7.7)</td>
</tr>
<tr>
<td><strong>Treatment of the first SC episode</strong></td>
<td></td>
</tr>
<tr>
<td>Antibiotics after onset of ARF/SC</td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>744/867 (86.1)</td>
</tr>
<tr>
<td>IM penicillin G benzathine</td>
<td>591/782 (75.6)</td>
</tr>
<tr>
<td>Oral penicillin</td>
<td>68/770 (8.8)</td>
</tr>
<tr>
<td>Oral amoxicillin</td>
<td>12/770 (1.6)</td>
</tr>
<tr>
<td><strong>Any immunotherapy given at first SC episode</strong></td>
<td></td>
</tr>
<tr>
<td>231/898 (25.7)</td>
<td></td>
</tr>
<tr>
<td>Steroids</td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>208/898 (23.2)</td>
</tr>
<tr>
<td>IM methylprednisolone</td>
<td>40/867 (4.6)</td>
</tr>
<tr>
<td>IM ACTH</td>
<td>16/867 (1.8)</td>
</tr>
<tr>
<td>Oral steroids</td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>167/881 (19.0)</td>
</tr>
<tr>
<td>Prednisone</td>
<td>111/848 (13.1)</td>
</tr>
<tr>
<td>Deflazacort or dexamethasone</td>
<td>4/845 (0.5)</td>
</tr>
<tr>
<td><strong>Duration of IV and oral steroid treatment at first episode, wk (n = 136/208)</strong></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>6.9 (8.8)</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>4.0 (2.4-8.0)</td>
</tr>
<tr>
<td><strong>IVIG</strong></td>
<td></td>
</tr>
<tr>
<td>21/898 (2.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Plasma exchange</strong></td>
<td></td>
</tr>
<tr>
<td>12/898 (1.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Time between SC symptom onset and first IT, d (n = 135/231)</strong></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>38.1 (86.5)</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>17.0 (10.0-30.0)</td>
</tr>
<tr>
<td><strong>Symptomatic pharmacological treatments given at first episode</strong></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>540/687 (78.6)</td>
</tr>
<tr>
<td>Haloperidol</td>
<td>241/663 (36.3)</td>
</tr>
<tr>
<td>Valproate</td>
<td>136/663 (20.5)</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>62/663 (9.4)</td>
</tr>
<tr>
<td><strong>Total weeks of symptomatic treatments at first episode (n = 169/540)</strong></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>18.9 (80.6)</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>8.0 (4.0-14.0)</td>
</tr>
</tbody>
</table>

(continued)
In total, 452 of 498 patients (90.8%) were hospitalized. The median (IQR) mRS score at nadir was 3 (3-4) in 460 patients; 139 of 460 patients (30.2%) had severe disease (mRS 4-5), including 28 of 234 patients (12.0%) with mRS score of 5 and complete loss of self-care skills. Other major manifestations of ARF included carditis or valvulitis in 610 of 1151 patients (53.0%), arthritisor arthralgia in 275 of 1118 patients (24.6%), and skin manifestations in 31 of 836 patients (3.7%).

Findings at the First Episode of Sydenham Chorea
Evidence of preceding streptococcal infection was reported in 559 of 655 patients (85.3%)\(^2\): elevated antistreptolysin O titer in 393 of 547 patients (71.8%), elevated anti-DNase B titer in 80 of 134 patients (59.7%), and GAS present in the throat culture for 68 of 182 patients (37.4%). Of 470 patients, 255 (54.3%) had elevated erythrocyte sedimentation rate, and 94 of 340 patients (27.6%) had elevated C-reactive protein (Table). Of 337 patients, 41 (12.2%) had a prolonged PR interval, and 16 of 177 patients (9.0%) had other electrocardiographic abnormalities. Of 225 patients, 43 (19.1%) had findings on brain magnetic resonance imaging, including 16 of 223 (7.2%) showing abnormal basal ganglia and 15 of 224 (6.7%) showing abnormal white matter. Of 153 patients, 84 (54.8%) had abnormal findings on electroencephalograms: 77 of 149 (51.7%) with slow or disorganized background activity and 7 of 147 (4.8%) with discharges or seizures. Of 32 patients, 8 (25.0%) had abnormal findings in cerebral spinal fluid, including 4 of 31 (12.9%) with pleocytosis and 2 of 26 (7.7%) with intrathecal oligoclonal bands; 0 of 30 patients had elevated CSF protein.

Treatment of the First Episode of Sydenham Chorea
Antibiotics were used as treatment in 744 of 867 patients (86.1%), and immunotherapy in 231 of 898 patients (25.7%): 208 of 898 patients (23.2%) received corticosteroids, 21 of 898 patients (2.3%) received intravenous immunoglobulin, and 12 of 898 patients (1.3%) received plasma exchange. Of 165 patients, 9 (5.5%) had adverse events associated with immunotherapy (eTable 5 in Supplement 1). Of 687 patients, 540 (78.6%) received symptomatic pharmacological treatments, including haloperidol for 241 of 663 patients (36.3%) and sodium valproate for 136 of 663 patients (20.5%). Clinician-reported benefit was most frequent for sodium channel blockers (carbamazepine in 18 patients, phenytoin in 2 patients; 18 of 20 patients [90.0%] with benefit) and antihistamines (hydroxyzine in 13 patients, diphenhydramine in 3 patients; 13 of 16 patients [81.2%] with benefit).
Figure 2. Patient Demographics and Clinician-Reported Response to Symptomatic Medications at the First Episode of Sydenham Chorea

Data are shown for the first episode of Sydenham chorea in 1325 patients with disease onset since 1945. The top 20 countries of 50 total are shown. Data on year of onset were available in 416 patients and inferred from year of publication in the remaining. Seven patients with disease onset after 32 years of age are not shown. Significance indicated for comparisons of proportion with clinician-reported benefit in pairwise χ² tests (Bonferroni-corrected).

- P = .001 vs sodium channel blockers.
- P < .001 vs sodium channel blockers.
- P = .04 vs antihistamines.
- P = .01 vs antihistamines.
- P < .001 vs antihistamines.
Of 408 patients, 36 (8.8%) had adverse events associated with symptomatic treatments, including 23 (5.6%) with severe adverse events (attributed to haloperidol in 13 patients, chlorpromazine and other phenothiazines in 9 patients, and sodium valproate in 1 patient) (eTable 7 in Supplement 1).

**Descriptive Data on Disease Course and Functional Outcome**
Median (IQR) duration of follow-up was 12 (5-37) months for 720 patients. There were no deaths.

**Chorea Duration and Disease Course**
Of 622 patients, 529 (85.0%) had full resolution of chorea at the first episode. The median (IQR) chorea duration was 3.0 (1.2-6.0) months (Figure 3A). Including all patients with available data on disease course, 263 of 766 patients (34.3%) experienced relapse; among them 171 of 240 (71.3%) relapsed once, 47 of 240 (19.6%) relapsed twice, 15 of 240 (6.3%) relapsed 3 times, and 7 of 240 (2.9%) experienced relapse 4 or more times (maximum 8 times). Median (IQR) interval to first relapse was 16.0 (8.3-48.0) months in 189 patients. Evidence of GAS infection was reported in 31 of 98 patients (31.6%) compared with 559 of 655 (85.3%) at the initial episode (P < .001).

**Functional Outcome**
Including all patients with available follow-up data, 138 of 595 patients (23.2%) had ongoing chorea at final follow-up, 28 of 472 patients (5.9%) had ongoing psychiatric or behavioral symptoms, and 12 of 395 patients (3.0%) had ongoing cognitive or school performance problems. Among patients with a final follow-up of 6 or more months after the last SC episode (or final mRS score of 0-1 at any time), 187 of 203 (92.1%) had an mRS score of 0 or 1 at final follow-up (median, 0; range, 0-3).

**Clinical and Treatment Factors Associated With Disease Course and Outcome**

**Chorea Duration**
We included 178 patients in the model for chorea duration at first episode (Figure 4A; eTable 8 in Supplement 1). Immunotherapy was associated with shorter chorea duration (hazard ratio [HR] for chorea resolution during treatment 1.51 [95% CI, 1.05-2.19]; P = .03). Carditis or valvulitis was associated with longer chorea duration (HR, 0.72 [95% CI, 0.52-0.99]; P = .04). The median chorea duration in 55 patients treated with 1 or more months of steroids was 1.2 months (95% CI, 1.2-2.0) vs 2.8 months (95% CI, 2.0-3.0) for 243 patients not treated with steroids (Tarone-Ware test P = .004; log-rank test P = .02). The median chorea duration for 55 patients treated for less than 1 month with...
steroids was 2.5 months (95% CI, 1.5-5.0), not significantly different from the groups with 1 or more months of treatment ($P = .08$) or no steroid treatment ($P = .84$) (Figure 3B).

**Disease Course**
We included 345 patients in the model for relapsing disease course (263 with relapse) (Figure 4B; eTable 8 in Supplement 1). Factors associated with relapsing course were arthritis or arthralgia (odds ratio [OR], 3.07 [95% CI, 1.15-8.17]; $P = .02$) and treatment with haloperidol at the first episode (OR, 2.02 [95% CI, 1.01-4.03]; $P = .046$). Factors associated with monophasic course were treatment with antibiotics (OR, 0.28 [95% CI, 0.09-0.85]; $P = .02$), corticosteroids (OR, 0.32 [95% CI, 0.15-0.67]; $P = .003$), or sodium valproate (OR, 0.33 [95% CI, 0.15-0.71]; $P = .004$). Compared with the odds for 184 patients not treated with steroids, the odds of experiencing a relapsing course were significantly lower (OR, 0.10 [95% CI, 0.04-0.25]; $P < .001$) among 33 patients treated for 1 or more months with steroids and significantly lower (OR, 0.31 [95% CI, 0.10-0.97]; $P = .03$) among 17 patients treated for less than 1 month with steroids. There was no significant difference in relapsing disease course between the treatment groups of less than 1 month and 1 or more months (OR, 0.34 [95% CI, 0.08-1.34]; $P = .12$).

**Functional Outcome**
We included 338 patients in the model for functional outcome (47 patients [13.9%] with poor outcome) (Figure 4C; eTable 8 in Supplement 1). Factors associated with poor outcome were treatment with plasma exchange (OR, 94.20 [95% CI, 12.51-709.19]; $P < .001$), history of other autoimmune or inflammatory diseases (OR, 6.02 [95% CI, 1.31-27.57]; $P = .02$) and younger age (<5 years) at disease onset (OR, 4.23 [95% CI, 1.17-15.27]; $P = .03$). Carditis or valvulitis was associated with good outcome (OR, 0.24 [95% CI, 0.10-0.56]; $P = .001$).
Discussion

To our knowledge, this individual patient data meta-analysis is the most comprehensive evidence synthesis to date for SC, including IPD from 1479 cases. We found that immunotherapy, in particular with corticosteroids, was associated with faster resolution of chorea at the first episode, and that antibiotics, corticosteroids, and sodium valproate were associated with lower rates of relapse, which occurred in 34.3% of patients overall. We found that 86.1% of patients had a good final functional outcome, but no treatment factors were identified in association with this.

Sydenham chorea was one of the earliest conditions recognized in neurology, and its distinctive features, including the full rheumatic syndrome recognized since 1889,333 give us some confidence that the disorder has been relatively consistently identified over time. We found that age at onset (median 10 years) and female preponderance (2.2:1)12 have remained almost constant for more than 100 years, while the frequencies of fever, arthritis or arthralgia, and poor functional outcome have reduced in the modern era (Figure 1). In the modern era, 12.0% of patients had complete loss of upper and lower limb function (possibly consistent with chorea paralytica). Psychiatric or behavioral symptoms were reported in 64.5% of patients, with formal psychiatric diagnoses (including attention-deficit/hyperactivity disorder or obsessive-compulsive disorder) assigned in 9.9% of patients. However, mental health specialist assessment was reported in only 17.6% of cases. In cohorts undergoing standardized psychiatric evaluations, rates of attention-deficit/hyperactivity disorder up to 31% and obsessive-compulsive disorder up to 24% have been reported.8,334

The median duration of chorea at the first episode was 3 months (Figure 3A), longer than reported in the era before 1945 and rising to 4 months in recent decades (Figure 1), perhaps due to increased recognition of subtle or fluctuating chorea. Immunotherapy was associated with shorter chorea duration, with significantly higher HR for chorea resolution during treatment (Figure 4A). Further analysis stratified by steroid treatment duration showed significantly shorter chorea duration (median 1.2 months) for patients receiving steroids for 1 or more months (Figure 3B). Our finding of benefit for steroids in hastening resolution of the acute SC episode is consistent with previous observational studies,5,7,11,335-341 and the only placebo-controlled RCT to date, in which 22 children receiving prednisone had a mean (SD) chorea duration of 1.8 (0.8) months vs 3.9 (2.8) months for placebo.15 Although we were unable to evaluate intravenous immunoglobulin specifically due to small numbers, this treatment has also been shown in an RCT to reduce the duration of symptomatic treatment required.16 The only factor associated with longer chorea duration in the present study was carditis or valvulitis, with a reduced HR for chorea resolution of 0.72. Carditis may indicate greater inflammatory activity and more severe disease6; a recent report similarly identified arthritis as a risk factor for longer chorea duration,17 although this finding was not replicated in the present study.

Symptomatic medications were used in 78.6% of patients. We did not find any associations with chorea duration; however, clinicians often reported benefit, most frequently for treatment with sodium channel blockers, such as carbamazepine,342,343 antihistamines, and second-generation antipsychotics (Figure 2D; eTable 6 in Supplement 1), none of which were associated with severe adverse events in the present study (eTable 7 in Supplement 1). Haloperidol was less frequently associated with benefit and more frequently associated with severe adverse events such as hypertonia or parkinsonism. In 1 study, 23% of SC patients receiving haloperidol required treatment change due to adverse effects344; SC has been hypothesized to be a risk factor for drug-induced parkinsonism.345

Relapse was reported in 34.3% of patients overall, similar to previous studies.9-11 We found that antibiotic treatment was associated with significantly reduced odds of relapsing course (Figure 4B),346 and as we were unable to account for treatment adherence, the actual benefit may exceed this value.7,9,17 Treatment with corticosteroids at the first episode was associated with 3.1-fold reduced odds of relapsing course. Although this association has been suggested in previous studies, it has not been previously observed with statistical significance.5,335,340 Additional analysis
confirmed that even steroid courses for less than 1 month were associated with monophasic disease course. Unexpectedly, treatment with sodium valproate was also associated with reduced odds of relapsing course. Valproate is regarded as a safe and efficacious treatment for symptom relief in SC\textsuperscript{342,344,347} but has not been previously associated with protection against relapse. Valproate is a histone deacetylase inhibitor that can induce epigenetic modifications to immune cells; in an ex vivo study of monocyte-derived macrophages from patients with systemic lupus erythematosus, valproate upregulated anti-inflammatory macrophages and cytokines while downregulating proinflammatory macrophages and tumor necrosis factor \( \alpha \textsuperscript{348} \). In animal models, valproate reduces inflammation in the optic nerve and spinal cord\textsuperscript{349,350}. As epigenetic modifications can be long-lasting, it is plausible that valproate could reduce relapse risk in SC; however, the proposed anti-inflammatory mechanisms are speculative and require further study. Conversely, treatment with haloperidol was associated with increased odds of relapsing course. It has been suggested that some SC recurrences may reflect a persisting susceptibility to movement disorder rather than true relapses of ARF\textsuperscript{9,351} and indeed, in the present study, evidence of GAS infection was less frequent at recurrence (31.6\%) than at presentation (85.3\%). One possibility is that some patients treated with haloperidol had such a susceptibility due to baseline differences (eg, worse disease severity or lower-resource health care settings), which we were unable to control for in our multivariable model. Another possibility is that haloperidol may induce long-term basal ganglia changes (as observed in first-episode psychosis\textsuperscript{352}), which could confer future susceptibility to dyskinesia in some patients, although this hypothesis remains to be adequately explored.

Poor functional outcome occurred in 13.9\% of patients. There is a well-described group of patients who develop chronic disease with persistent chorea or psychiatric symptoms\textsuperscript{16–8} despite no evidence of immunological difference from patients in remission and no structural brain injury, although abnormalities suggestive of neuronal loss in the basal ganglia have been reported from magnetic resonance spectroscopy\textsuperscript{353,354}. We found that patients with poor outcome were more likely to be younger than 5 years at onset, undergo plasma exchange, and have comorbid autoimmune or inflammatory disorders; they were also less likely to have carditis or valvulitis (Figure 4C). Plasma exchange is rarely used in SC and is mainly used as rescue therapy after failure of other treatments.\textsuperscript{355} Hence, the association with poor outcome likely reflects a severity bias, which our main severity measure (mRS score \( \geq 4 \)) may not capture. Other treatments were not significantly associated with long-term outcome in the present study; however a previous RCT showed benefit for intravenous immunoglobulin therapy in more subtle functional outcome measures\textsuperscript{356}. The association of carditis with good functional outcome is contrary to previous studies of prolonged SC\textsuperscript{6} and remains to be explained; it could be that some patients in the poor outcome group had additional or alternative neurological disorders that were not associated with carditis.

Limitations

The main limitations of this meta-analysis were the retrospective nature of the data, inclusion of articles only in a subset of languages, underrepresentation of low and lower-middle income countries (Table), and inclusion of case reports that were susceptible to diagnostic error (especially in older cohorts, when, for example, N-methyl-d-aspartate receptor antibody testing was not available) and reporting biases, such as reporting patients with worse disease, atypical features (eg, abnormal findings on magnetic resonance imaging), or atypical treatment response. The data on clinician-reported benefit from symptomatic medications may be especially subject to such biases, and the medications evaluated as most beneficial in this analysis were given to relatively small numbers of patients. Estimates of feature frequencies may be biased by underreporting of negative findings or conversely by underreporting of more subtle positive findings (eg, individual psychiatric symptoms). Adverse treatment effects were also likely underreported. Data collected were limited by heterogeneous availability, hence hot-deck imputation was used to enable multivariable analysis. Although this method generates clinically plausible values (by constraining imputation to values already present in the database), it does not guarantee complete extinction of bias, as implicit
assumptions are required in the choice of metric to match donors to recipients. As data were missing not at random, sensitivity analyses were conducted for year of onset and missingness (eMethods 3, eTables 9-17 in Supplement 1); however, the main findings for immunotherapy, corticosteroids, and valproate were supported by sensitivity analyses on reduced data sets (eTables 9-17 in Supplement 1). Functional outcome evaluation as good vs poor was a pragmatic grouping of different outcome measures (mRS, persisting chorea, or psychiatric or behavioral symptoms), necessary to enable analysis of heterogeneously reported data. We acknowledge that this grouping may oversimplify important patient differences, and the predictor variables may not capture all patient complexities, potentially explaining some associations between treatments and adverse outcomes.

Conclusions

This meta-analysis found evidence to support the use of immunotherapy, in particular corticosteroids, to reduce the duration of chorea at the first episode of SC and to support the use of antibiotics, corticosteroids, and sodium valproate to reduce the risk of relapse, although the mechanism of action for valproate is not fully understood and requires further investigation. Most patients achieved a good final functional outcome; however, specific treatment factors associated with this outcome remain unknown. This synthesis should help direct future research questions and is forming the base for an ongoing international effort with Delphi methodology to provide consensus-based recommendations for the management of SC.
Drafting of the manuscript: Eyre, Ferrarin, Zuberi, Morton, Dale, Lim, Nosadini.

Critical review of the manuscript for important intellectual content: All authors.

Statistical analysis: Eyre, Molteni.

Obtained funding: Lim.

Administrative, technical, or material support: Ferrarin, Khamis, Zuberi, Newlove-Delgado, Morton.

Supervision: Zuberi, Molteni, Dale, Lim, Nosadini.

Conflict of Interest Disclosures: Dr Ferrarin reported being a permanent collaborator of the Sydenham's Chorea Association. Dr Sie reported being the chair of the Sydenham's Chorea Association. Dr Newlove-Delgado reported receiving grants from the British Association for Childhood Disability, British Medical Association Helen Lawton Award, and Sydenham's Chorea Association during the conduct of the study. Dr Morton reported being the honorary president of the Sydenham's Chorea Association. Dr Molteni reported receiving support from the Medical Research Council Skills Development Fellowship Scheme. Dr Dale reported receiving support from National Health and a Medical Research Council Investigator grant (Australia), and the Petre Foundation. Dr Lim reported receiving personal fees from Octapharma, Roche, Novartis, Amgen; receiving grants from the Dancing Eye Syndrome Society, Great Ormond Street Hospital Charity, Multiple Sclerosis Society UK, and the Sparks Charity; receiving research support grants from the London Clinical Research Network and the Evelina Appeal, National Institute of Health Research, Action Medical Research, Boston Children's Hospital Research Fund, and the GOSH charity outside the submitted work; and being the UK Clinical lead for the MR-MinMo study. No other disclosures were reported.

Funding/Support: Dr Eyre was supported by Action Medical Research (GN2835) and the British Paediatric Neurology Association. Dr Nosadini was supported by the University of Padova (DOR2323722).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: The members of the Sydenham's Chorea Systematic Literature Review Working Group are listed in Supplement 2.

Data Sharing Statement: See Supplement 3.

Additional Contributions: We thank the Sydenham's Chorea Association (sydenhamschorea.com) for supporting this project and offering to guarantee expenses in the project development phase. We thank Laura Ciolfi (Scientific and Patient Library, Centro di Riferimento Oncologico di Aviano, IRCCS, Aviano, Italy) who gave support for the bibliographic search, Andrea Parro (Scientific and Patient Library, Centro di Riferimento Oncologico di Aviano, IRCCS, Aviano, Italy) who supported us in the retrieval of full texts, and Eva Wooding, MD, (University of Exeter Medical School, Exeter, UK) and Alexander Simpson, MD, (Royal Hospital for Children & Young People, Edinburgh, UK) who contributed to the working group formulating the scope of the systematic review. They were not compensated beyond their usual salaries for the stated contributions.

REFERENCES


130. Schwarz H. Chorea gravis (Sydenham's chorea) treated with cortisone and ascorbic acid. CMAJ. 1951;65(2):150-151.


144. de Carvalho JF, Churilov LP. Sydenham's chorea as the first manifestation of rheumatic fever in two boys. Medit J Rheumatol. 2021;32(4):369-372. doi:10.31138/mjr.32.4.369


Branson WP. A clinical study on the avenues of rheumatic infection: based upon examination of 75 cases of Sydenham's chorea. BMJ. 1912;2(2708):1429-1432. doi:10.1136/bmj.2.2708.1429


Web references:


328. Cheadle WB. The Various Manifestations of the Rheumatic State as Exemplified in Childhood and Early Life. Smith. Elder; 1889.


345. Teixeira AL, Cardoso F, Maia DP, Cunningham MC. Sydenham’s chorea may be a risk factor for drug-induced parkinsonism. J Neurol Neurosurg Psychiatry. 2003;74(9):1350-1351. doi:10.1136/jnnp.74.9.1350-a


SUPPLEMENT 1.
eMethods 1. Literature Search and Data Collection

eMethods 2. Statistical Analysis

eMethods 3. Sensitivity Analysis

eFigure 1. PRISMA Flow Diagram

eFigure 2. Symptom Frequencies Among Patients With Reported Psychiatric/Behavioural Symptoms

eTable 1. Literature Search and Record Selection: Databases Searched and Numbers of Records Retrieved, Screened and Included
eTable 2. Proportionsof Missing (Imputed) Data in the Multivariable Models

eTable 3. Historical Comparison of Patients With Disease Onset Before and After 1945

eTable 4. Complete Descriptive Data in 1325 Patients with Sydenham's Chorea Since 1945

eTable 5. Adverse Events Associated With Immunotherapy

eTable 6. Clinician-Reported Benefit From Symptomatic Medications

eTable 7. Adverse Events Associated With Symptomatic Medications

eTable 8. Multivariable Model Results

eTable 9. Data Missingness According to Year of Disease Onset

eTable 10. Nested Model for Chorea Duration at First Episode With Twentieth Century Cases Withheld

eTable 11. Nested Model for Relapsing Disease Course With Twentieth Century Cases Withheld

eTable 12. Nested Model for Poor Functional Outcome With Twentieth Century Cases Withheld

eTable 13. Outcome Distributions for Variables With High Missingness in the Chorea Duration at First Episode Model

eTable 14. Outcome Distributions for Variables With High Missingness in the Relapsing Disease Course Model

eTable 15. Outcome Distributions for Variables With High Missingness in the Poor Functional Outcome Model

eTable 16. Nested Model for Chorea Duration at First Episode With Cases Missing Data in ≥1 Missing Not at Random (MNAR) Variables Withheld

eTable 17. Nested Model for Poor Functional Outcome with Cases Missing Data in ≥1 Missing Not at Random (MNAR) Variables Withheld

SUPPLEMENT 2.

Nonauthor Collaborators. Members of the Sydenham's Chorea Systematic Literature Review Working Group

SUPPLEMENT 3.

Data Sharing Statement